Amy Baxter

A Johns Hopkins surgeon, Marty Makary also serves as a board member or adviser to several companies, including one that offers compounded GLP-1 drugs.

Zevra Therapeutics is building a commercial strategy for an ultra-small patient pool.

The agency has yet to make a decision about keeping tirzepatide on or off of its shortage list — letting compound pharmacies continue their lucrative operations for now.

With a little more certainty coming to the market, the R&D environment in 2025 will be about pipeline prioritization and accelerating M&A.

The pharma giant is looking for another edge in the competitive weight loss market through DTC expansion.

In This Article LLY PFE This story was originally published on PharmaVoice . To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter

How regulators could hit PBMs from multiple sides in the coming year.

A wave of new weight loss treatments is on the way, and drugmakers are scrambling for a foot in the door.

CMS is expected to publish up to 15 drugs for the second cycle of the program by Feb. 1, and these are some of the drugs most likely to make the list.

Novel drug approvals have set the stage for more breakthroughs in pharma.